Pfizer and MMV to develop malaria treatment
This article was originally published in Scrip
Executive Summary
Pfizer and the not-for-profit organisation Medicines for Malaria Venture (MMV) marked World Malaria Day (on 25 April) by signing an agreement to develop a fixed-dose combination product for the intermittent preventative treatment of Plasmodium falciparum malaria in pregnancy.